Abstract:Prion diseases are a group of rare and fatal neurodegenerative diseases caused by the cellular prion protein, PrP , misfolding into the infectious form, PrP , which forms aggregates in the brain. This leads to activation of glial cells, neuroinflammation, and irreversible neuronal loss, however, the role of glial cells in prion disease pathogenesis and neurotoxicity is poorly understood. Microglia can phagocytose PrP , leading to the release of inflammatory signaling molecules, which subsequently induce astrocyte reactivity. Animal models show highly upregulated inflammatory molecules that are a product of the Nuclear Factor-kappa B (NF-κB) signaling pathway, suggesting that this is a key regulator of inflammation in the prion-infected brain. The activation of the IκB kinase complex (IKK) by cellular stress signals is critical for NF-κB-induced transcription of a variety of genes, including pro-inflammatory cytokines and chemokines, and regulators of protein homeostasis and cell survival. However, the contribution of microglial IKK and NF-κB signaling in the prion-infected brain has not been evaluated. Here, we characterize a primary mixed glial cell model containing wild-type (WT) astrocytes and IKK knock-out (KO) microglia. We show that, when exposed to prion-infected brain homogenates, NF-κB-associated genes are significantly downregulated in mixed glial cultures containing IKK KO microglia. Mice with IKK KO microglia show rapid disease progression when intracranially infected with prions, including an increase in microglia and reactive astrocytes, and accelerated loss of hippocampal neurons and associated behavioral deficits. These animals display clinical signs of prion disease early and have a 22% shorter life expectancy compared to infected wild-type mice. Intriguingly, PrP accumulation was significantly lower in the brains of infected animals with IKK KO microglia compared to age-matched controls, suggesting that accelerated disease is independent of PrP accumulation, highlighting a glial-specific pathology. Conversely, primary mixed glia with IKK KO microglia have significantly more PrP accumulation when exposed to infected brain homogenates. Together, these findings present a critical role in NF-κB signaling from microglia in host protection suggesting that microglial IKK may be involved in sufficient clearance of prions.

Retraction Note To: Early Minocycline and Late FK506 Treatment Improves Survival and Alleviates Neuroinflammation, Neurodegeneration, and Behavioral Deficits in Prion-Infected Hamsters.

Combinatory FK506 and Minocycline Treatment Alleviates Prion-Induced Neurodegenerative Events Via Caspase-Mediated MAPK-NRF2 Pathway.

Infection of Prions and Treatment of PrP106–126 Alter the Endogenous Status of Protein 14-3-3 and Trigger the Mitochondrial Apoptosis Possibly via Activating Bax Pathway

Abnormal Activation of Microglia Accompanied with Disrupted CX3CR1/CX3CL1 Pathway in the Brains of the Hamsters Infected with Scrapie Agent 263K.

Remarkable Reduction of MAP2 in the Brains of Scrapie-Infected Rodents and Human Prion Disease Possibly Correlated with the Increase of Calpain

Treatment of Scrapie Pathogen 263k with Tetracycline Partially Abolishes Protease-Resistant Activity in Vitro and Reduces Infectivity in Vivo

The Brain NO Levels and NOS Activities Ascended in the Early and Middle Stages and Descended in the Terminal Stage in Scrapie-Infected Animal Models

Targeting Neuroinflammation by Pharmacologic Downregulation of Inflammatory Pathways Is Neuroprotective in Protein Misfolding Disorders

Therapeutic window for treatment of prion disease defined by timed depletion of Prion protein

Targeting neuroinflammation by pharmacologic down-regulation of inflammatory pathways is neuroprotective in protein misfolding disorders

Inhibitors of the Mitogen-Activated Protein Kinase Kinase 1/2 Signaling Pathway Clear Prion-Infected Cells from PrPSc

Reduction of NF-κB (p65) in Scrapie-Infected Cultured Cells and in the Brains of Scrapie-Infected Rodents.

Microglia-specific NF-κB signaling is a critical regulator of prion-induced glial inflammation and neuronal loss

Down-regulation of Brain-Derived Neurotrophic Factor and Its Signaling Components in the Brain Tissues of Scrapie Experimental Animals.

Prion therapeutics: Lessons from the past

Minocycline reduces neuroinflammation but does not ameliorate neuron loss in a mouse model of neurodegeneration

Chronic Treatment With Minocycline Preserves Adult New Neurons And Reduces Functional Impairment After Focal Cerebral Ischemia

PrP turnover in vivo and the time to effect of prion disease therapeutics

Antisense oligonucleotides extend survival of prion-infected mice

Anti-prion drugs do not improve survival in novel knock-in models of inherited prion disease

Stimulations of the Culture Medium of Activated Microglia and TNF-Alpha on a Scrapie-Infected Cell Line Decrease the Cell Viability and Induce Marked Necroptosis That Also Occurs in the Brains from the Patients of Human Prion Diseases